Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aminolevulinic acid
Drug ID BADD_D00110
Description A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indications and Usage Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Marketing Status Prescription
ATC Code L01XD04
DrugBank ID DB00855
KEGG ID D07567
MeSH ID D000622
PubChem ID 137
TTD Drug ID D0Y7ZD
NDC Product Code 46016-5450
Synonyms Aminolevulinic Acid | Acid, Aminolevulinic | Delta-Aminolevulinic Acid | Acid, Delta-Aminolevulinic | Delta Aminolevulinic Acid | Levulan | 5-Aminolaevulinate | 5 Aminolaevulinate | 5-Aminolevulinate | 5 Aminolevulinate | Aminolevulinic Acid Hydrochloride | Acid Hydrochloride, Aminolevulinic | Hydrochloride, Aminolevulinic Acid
Chemical Information
Molecular Formula C5H9NO3
CAS Registry Number 106-60-5
SMILES C(CC(=O)O)C(=O)CN
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hemiparesis17.01.04.001--
Herpes simplex11.05.02.001; 23.09.03.001--Not Available
Hyperaesthesia17.02.06.004--Not Available
Hyperkeratosis23.01.01.001--
Hypersensitivity10.01.03.0030.001066%
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.0100.000799%
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001--Not Available
Nausea07.01.07.0010.000799%
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Oedema08.01.07.006; 14.05.06.0100.000799%Not Available
Pain08.01.08.0040.001332%
Paraesthesia17.02.06.005--
Petechiae01.01.03.002; 23.06.01.003; 24.07.06.004--Not Available
Photophobia06.01.01.004; 17.17.02.0060.000533%
Photosensitivity reaction23.03.09.0030.000533%
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash pustular11.01.12.002; 23.03.10.003--
Respiratory failure14.01.04.003; 22.02.06.002--
Scab23.03.03.004--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
Skin cancer16.03.02.002; 23.08.02.002--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene